VERY EARLY MOLECULAR RESPONSE AT 1 MONTH CAN PREDICT 12-MONTH MAJOR MOLECULAR RESPONSE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TREATED WITH TKIS

被引：0
|
作者：
Song, H. Y. [1 ]
Choi, S. Y. [1 ]
Lee, S. E. [1 ,2 ]
Kim, S. H. [1 ]
Yoo, H. L. [1 ]
Lee, M. Y. [1 ]
Hwang, H. J. [1 ]
Kang, K. H. [1 ]
Kee, K. M. [1 ]
Kim, D. W. [1 ,2 ]
机构：
[1] Catholic Univ Korea, Catholic Leukemia Res Inst, Seoul, South Korea
[2] Catholic Univ Korea, Dept Hematol, Seoul St Marys Hosp, Seoul, South Korea
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1103
引用
收藏
页码：456 / 456
页数：1
相关论文
共 50 条
  • [41] Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study
    Malagola, Michele
    Iurlo, Alessandra
    Abruzzese, Elisabetta
    Bonifacio, Massimiliano
    Stagno, Fabio
    Binotto, Gianni
    D'Adda, Mariella
    Lunghi, Monia
    Crugnola, Monica
    Ferrari, Maria Luisa
    Lunghi, Francesca
    Castagnetti, Fausto
    Rosti, Gianantonio
    Lemoli, Roberto M.
    Sancetta, Rosaria
    Coppi, Maria Rosaria
    Corsetti, Maria Teresa
    Cambrin, Giovanna Rege
    Romano, Atelda
    Tiribelli, Mario
    Rossi, Antonella Russo
    Russo, Sabina
    Aprile, Lara
    Bocchia, Monica
    Gandolfi, Lisa
    Farina, Mirko
    Bernardi, Simona
    Polverelli, Nicola
    Roccaro, Aldo M.
    De Vivo, Antonio
    Baccarani, Michele
    Russo, Domenico
    CANCER MEDICINE, 2021, 10 (05): : 1726 - 1737
  • [42] Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
    Okamoto, Yuji
    Hirano, Mitsuhito
    Morino, Kai
    Kajita, Masashi K.
    Nakaoka, Shinji
    Tsuda, Mayuko
    Sugimoto, Kei-ji
    Tamaki, Shigehisa
    Hisatake, Junichi
    Yokoyama, Hisayuki
    Igarashi, Tadahiko
    Shinagawa, Atsushi
    Sugawara, Takeaki
    Hara, Satoru
    Fujikawa, Kazuhisa
    Shimizu, Seiichi
    Yujiri, Toshiaki
    Wakita, Hisashi
    Nishiwaki, Kaichi
    Tojo, Arinobu
    Aihara, Kazuyuki
    NPJ SYSTEMS BIOLOGY AND APPLICATIONS, 2022, 8 (01)
  • [43] Early molecular response in chronic myeloid leukemia and halving time: Latest evidences
    Brectia, Massimo
    Molica, Matteo
    Colafigli, Gioia
    Massaro, Fulvio
    Alimena, Giuliana
    LEUKEMIA RESEARCH, 2016, 48 : 20 - 25
  • [44] Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
    Yuji Okamoto
    Mitsuhito Hirano
    Kai Morino
    Masashi K. Kajita
    Shinji Nakaoka
    Mayuko Tsuda
    Kei-ji Sugimoto
    Shigehisa Tamaki
    Junichi Hisatake
    Hisayuki Yokoyama
    Tadahiko Igarashi
    Atsushi Shinagawa
    Takeaki Sugawara
    Satoru Hara
    Kazuhisa Fujikawa
    Seiichi Shimizu
    Toshiaki Yujiri
    Hisashi Wakita
    Kaichi Nishiwaki
    Arinobu Tojo
    Kazuyuki Aihara
    npj Systems Biology and Applications, 8
  • [45] Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia
    Lee, Sung-Eun
    Choi, Soo Young
    Oh, Yun Jeong
    Kim, Soo-Hyun
    Song, Hye-Young
    Yoo, Hea-Lyun
    Lee, Mi-Young
    Chae, Moon-Jung
    Kang, Ki-Hoon
    Hwang, Hee-Jeong
    Jang, Eun-Jung
    Kim, Dong-Wook
    LEUKEMIA RESEARCH, 2015, 39 (04) : 411 - 418
  • [46] ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase
    Ernst, Thomas
    Schoenfeld, Lioba
    Rinke, Jenny
    Hinze, Anna
    Nagel, Saskia N.
    Schaefer, Vivien
    Schenk, Thomas
    Fabisch, Christian
    Bruemmendorf, Tim H.
    Burchert, Andreas
    le Coutre, Philipp
    Krause, Stefan W.
    Saussele, Susanne
    Safizadeh, Fatemeh
    Pfirrmann, Markus
    Hochhaus, Andreas
    BLOOD, 2022, 140
  • [47] The Achievement of An Early Complete Cytogenetic Response (CCyR) Is A Major Determinant for Outcome In Patients (pts) with Early Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)
    Jabbour, Elias
    Kantarjian, Hagop M.
    Shan, Jenny
    O'Brien, Susan
    Kadia, Tapan
    Borthakur, Gautam
    Quintas-Cardama, Alfonso
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Cortes, Jorge
    BLOOD, 2010, 116 (21) : 1405 - 1405
  • [48] ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
    Schoenfeld, Lioba
    Rinke, Jenny
    Hinze, Anna
    Nagel, Saskia N.
    Schaefer, Vivien
    Schenk, Thomas
    Fabisch, Christian
    Bruemmendorf, Tim H.
    Burchert, Andreas
    le Coutre, Philipp
    Krause, Stefan W.
    Saussele, Susanne
    Safizadeh, Fatemeh
    Pfirrmann, Markus
    Hochhaus, Andreas
    Ernst, Thomas
    LEUKEMIA, 2022, 36 (09) : 2242 - 2249
  • [49] ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
    Lioba Schönfeld
    Jenny Rinke
    Anna Hinze
    Saskia N. Nagel
    Vivien Schäfer
    Thomas Schenk
    Christian Fabisch
    Tim H. Brümmendorf
    Andreas Burchert
    Philipp le Coutre
    Stefan W. Krause
    Susanne Saussele
    Fatemeh Safizadeh
    Markus Pfirrmann
    Andreas Hochhaus
    Thomas Ernst
    Leukemia, 2022, 36 : 2242 - 2249
  • [50] Impact of quantitative molecular response on the evolution of chronic myeloid leukemia treated with imatinib mesylate
    Nicolini, Franck
    HEMATOLOGIE, 2006, 12 (04): : 226 - 227
12345